S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)

Madrigal Pharmaceuticals (MDGL) Competitors

$251.63
+15.43 (+6.53%)
(As of 03/1/2024 ET)

MDGL vs. FOLD, ALKS, IONS, IRWD, DVAX, LGND, YMAB, GBIO, UTHR, and BMRN

Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Amicus Therapeutics (FOLD), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Ironwood Pharmaceuticals (IRWD), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Y-mAbs Therapeutics (YMAB), Generation Bio (GBIO), United Therapeutics (UTHR), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "pharmaceutical preparations" industry.

Madrigal Pharmaceuticals vs.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

79.9% of Madrigal Pharmaceuticals shares are owned by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Madrigal Pharmaceuticals has a beta of -0.48, indicating that its stock price is 148% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Amicus Therapeutics received 75 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 73.42% of users gave Amicus Therapeutics an outperform vote while only 68.55% of users gave Madrigal Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Madrigal PharmaceuticalsOutperform Votes
436
68.55%
Underperform Votes
200
31.45%
Amicus TherapeuticsOutperform Votes
511
73.42%
Underperform Votes
185
26.58%

In the previous week, Madrigal Pharmaceuticals had 21 more articles in the media than Amicus Therapeutics. MarketBeat recorded 44 mentions for Madrigal Pharmaceuticals and 23 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 0.66 beat Madrigal Pharmaceuticals' score of 0.47 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
12 Very Positive mention(s)
2 Positive mention(s)
12 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amicus Therapeutics
6 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Madrigal Pharmaceuticals currently has a consensus target price of $294.14, suggesting a potential upside of 21.49%. Amicus Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 33.14%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Amicus Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Amicus Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A-$295.35M-$19.94-12.15
Amicus Therapeutics$372.37M10.50-$236.57M-$0.51-26.14

Madrigal Pharmaceuticals has a net margin of 0.00% compared to Amicus Therapeutics' net margin of -37.96%. Amicus Therapeutics' return on equity of -130.90% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal PharmaceuticalsN/A -406.28% -128.41%
Amicus Therapeutics -37.96%-130.90%-20.72%

Summary

Amicus Therapeutics beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.


Get Madrigal Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDGL vs. The Competition

MetricMadrigal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.78B$6.76B$4.98B$7.56B
Dividend YieldN/A2.82%2.87%3.87%
P/E Ratio-12.1510.01198.2614.62
Price / SalesN/A225.483,058.9375.64
Price / CashN/A19.1096.0754.95
Price / Book20.994.874.554.70
Net Income-$295.35M$158.07M$114.14M$211.39M
7 Day Performance2.41%7.17%5.28%3.03%
1 Month Performance9.00%13.96%9.81%5.85%
1 Year Performance-13.23%7.82%13.45%9.15%

Madrigal Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FOLD
Amicus Therapeutics
4.1282 of 5 stars
$13.70
-0.4%
$17.20
+25.5%
-2.8%$4.02B$329.23M-23.22484Analyst Report
Short Interest ↑
News Coverage
ALKS
Alkermes
2.7712 of 5 stars
$30.39
-5.6%
$32.50
+6.9%
+11.0%$5.07B$1.66B14.682,280Positive News
IONS
Ionis Pharmaceuticals
3.7268 of 5 stars
$44.35
-0.2%
$49.80
+12.3%
+25.9%$6.36B$587M-15.45796Short Interest ↑
IRWD
Ironwood Pharmaceuticals
4.1495 of 5 stars
$14.83
+1.7%
$21.00
+41.6%
-16.3%$2.32B$442.73M-2.28219Analyst Downgrade
Options Volume
News Coverage
DVAX
Dynavax Technologies
4.4517 of 5 stars
$12.28
-1.0%
$25.00
+103.6%
+23.0%$1.60B$361.18M31.49351
LGND
Ligand Pharmaceuticals
4.9085 of 5 stars
$72.37
-1.8%
$116.33
+60.7%
+10.0%$1.26B$196.24M106.4376Analyst Report
YMAB
Y-mAbs Therapeutics
0.5119 of 5 stars
$16.55
+1.6%
$14.17
-14.4%
+339.5%$721.91M$65.27M-37.61147News Coverage
Gap Up
GBIO
Generation Bio
4.0817 of 5 stars
$1.97
-7.5%
$8.56
+334.4%
-36.6%$130.18MN/A-0.99150Upcoming Earnings
Positive News
UTHR
United Therapeutics
4.9783 of 5 stars
$214.16
-0.3%
$292.80
+36.7%
-8.3%$10.06B$1.94B11.80985Positive News
BMRN
BioMarin Pharmaceutical
4.8225 of 5 stars
$88.67
-0.1%
$110.16
+24.2%
-13.4%$16.70B$2.10B115.163,082Analyst Report
Analyst Revision

Related Companies and Tools

This page (NASDAQ:MDGL) was last updated on 3/1/2024 by MarketBeat.com Staff